AD 214 - Addpharma
Alternative Names: AD 214-02; AD-214 - AddpharmaLatest Information Update: 28 Sep 2023
At a glance
- Originator Addpharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Gastro-oesophageal reflux
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux in South Korea (PO, Tablet)
- 29 Mar 2022 Addpharma completes a phase-I clinical trial in Gastro-oesophageal reflux (In volunteers) in South Korea (PO) (NCT05062876)
- 19 Oct 2021 Phase-I clinical trials in Gastro-oesophageal reflux (In volunteers) in South Korea (PO) (NCT05062876)